Bron J
Cedona Pharmaceuticals BV, Haarlem, The Netherlands.
Biopharm Drug Dispos. 1988 Jan-Feb;9(1):97-111. doi: 10.1002/bod.2510090110.
The aim of the present study was to evaluate the bioavailability of a new tablet formulation of carbocysteine relative against two other oral carbocysteine containing dosage forms, viz. a syrup and capsules. Plasma levels and urine concentrations of carbocysteine were monitored, following oral administration of all three dosage forms to healthy human volunteers, by direct derivatization of carbocysteine using dabsylchloride and subsequent high performance liquid chromatography. There was no difference in bioavailability of carbocysteine from these dosage forms as expressed by the respective areas under the plasma concentration-time curves and total amounts of unchanged carbocysteine excreted in urine.
本研究的目的是评估半胱氨酸新片剂制剂相对于其他两种含半胱氨酸的口服剂型（即糖浆剂和胶囊剂）的生物利用度。通过使用丹磺酰氯对半胱氨酸进行直接衍生化，随后进行高效液相色谱法，在向健康人类志愿者口服这三种剂型后，监测了半胱氨酸的血浆水平和尿液浓度。以血浆浓度-时间曲线下的相应面积和尿液中排泄的未变化半胱氨酸总量表示，这些剂型的半胱氨酸生物利用度没有差异。
